| 期刊論文1. | 蔡慧珊(2003)。無許可證及非仿單標示處方於兒童之安全性。成醫藥誌,13(1),1-3。 延伸查詢 | 2. | King, Jaime Staples、Moulton, Benjamin W.(2006)。Rethinking informed consent: The case for shared medical decision-making。American Journal of Law & Medicine,32(4),429-501。 | 3. | 汪紹銘(20071200)。藥品仿單外之使用(Off-Label Use)之法律問題。全國律師,11(12),73-81。 延伸查詢 | 4. | Radley, David C.、Finkelstein, Stan N.、Stafford, Randall S.(2006)。Off-label Prescribing Among Office-Based Physicians。Archives of Internal Medicine,166(9),1021-1026。 | 5. | Gorman, Christine(19950918)。Double-Duty Drugs。TIME,1995(Sep.)。 | 6. | Kocs, Darren、Fendrick, A. Mark(2003)。Effect of Off-label Use of Oncology Drugs on Pharmaceutical Costs: The Rituximab Experience。American Journal of Managed Care,9,393-400。 | 7. | Eastman, Peggy(2005)。Reimbursement Policies Discourage Off-label Drug Use。Oncology Times,27(20),8-10。 | 8. | Rayburn, William F.、Farmer, Kevin C.(1997)。Off-label Prescribing during Pregnancy。Obstetrics and Gynecology Clinics of North America,24(3),471-478。 | 9. | Conroy, Sharon、Choonara, Imti、Impicciatore, Piero、Mohn, Angelika、Arnell, Henrik、Rane, Anders、Knoeppel, Carmen、Seyberth, Hannsjoerg、Pandolfini, Chiara、Raffaelli, Maria Pia、Rocchi, Francesca、Bonati, Maurizio、Jong, Geert't、de Hoog, Matthijs、van den Anker, John(2000)。Survey of Unlicensed and Off Label Drug Use in Paediatric Wards in European Countries。British Medical Journal,320(7227),79-82。 | 10. | 吳俞樺、蕭介民、洪國全、洪志鵬、鹿曉楓、曾稼志(20050900)。Intrathecal Midazolam Combined with Low-dose Bupivacaine Improves Postoperative Recovery in Diabetic Mellitus Patients Undergoing Foot Debridement。麻醉學雜誌,43(3),129-134。 延伸查詢 | 11. | Hofmeyr, G. J.、Gülmezoglu, A. M.、Alfirevic, Z.(1999)。Misoprostol for Induction of Labour: A Systematic Review。BJOG: An International Journal of Obstetrics & Gynaecology,106(8),798-803。 | 12. | Wagner, Marsden(2005)。Off-label Use of Misoprostol in Obstetrics: A Cautionary Tale。BJOG: An International Journal of Obstetrics & Gynaecology,112(3),266-268。 | 13. | Beck, James M.、Azari, Elizabeth D.(1998)。FDA, Off-Label Use, and Informed Consent: Debunking Myths and Misconceptions。Food and Drug Law Journal,53(1),71-104。 | 14. | 楊秀儀(20050600)。美國「告知後同意」法則之考察之分析。月旦法學,121,138-152。 延伸查詢 | 研究報告1. | (2008)。高雄縣政府醫師懲戒委員會2008年1月22日府衛醫字第0970002762號決議書。 延伸查詢 | 學位論文1. | 許杏如(2009)。藥品仿單標示外使用(Off-Label Use)之民事責任與藥害填補機制(碩士論文)。國立成功大學。 延伸查詢 | 圖書1. | World Health Organization(2007)。WHO Model List of Essential Medicines。 | 2. | Fuller, Lon L.(1977)。The Morality of Law。Yale University Press。 | 單篇論文1. | National Institute for Health and Clinical Excellence(2008)。Induction of labor。 | 2. | American College of Obstetricians and Gynecologists(2009)。Induction of labor。 | 其他1. | Association of Community Cancer Centers,Covance Market Access Services, Inc.(2008)。Impact of Payer Coverage and Reimbursement Policies on Off-Label Use of Anticancer Therapies,http://accc-cancer.org/advocacy/pdf/off-label_survey_report_2008.pdf。 | 2. | Abdel-Aleem, H.(2009)。Misoprostol for Cervical Ripening and Induction of Labour: RHL commentary,http://apps.who.int/rhl/pregnancy_childbirth/induction/CD000941_abdel-aleemh_com/en/index.html。 | 3. | Food and Drug Administration(2009)。Misoprostol (marketed as Cytotec) Information,http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm111315.htm。 | |